TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:37
AYTU BIOPHARMA INC ( AYTU ) https://aytubio.com
1.53USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-48.72%
AYTU
SPY
32.66%
-94.44%
AYTU
SPY
108.59%
-99.22%
AYTU
SPY
302.52%
AYTU
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
13.95
6.13
0.03
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.23
0.18
0.47
-18.45
0.00
-4.57
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-5.61
72.31
-1.94
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
-2.2672
-9.25
-7.43
-1.79
Other Earnings and Cash Flow Stats:
AYTU BIOPHARMA INC ( AYTU ) Net Income TTM ($MM) is -6.25
AYTU BIOPHARMA INC ( AYTU ) Operating Income TTM ($MM) is -4.68
AYTU BIOPHARMA INC ( AYTU ) Owners' Earnings Annual ($MM) is 0.00
AYTU BIOPHARMA INC ( AYTU ) Current Price to Owners' Earnings ratio is 0.00
AYTU BIOPHARMA INC ( AYTU ) EBITDA TTM ($MM) is 2.42
AYTU BIOPHARMA INC ( AYTU ) EBITDA Margin is -1.94%
Capital Allocation:
AYTU BIOPHARMA INC ( AYTU ) has paid 0.00 dividends per share and bought back -3.619601 million shares in the past 12 months
AYTU BIOPHARMA INC ( AYTU ) has reduced its debt by 3.832 million USD in the last 12 months
Capital Structure:
AYTU BIOPHARMA INC ( AYTU ) Interest-bearing Debt ($MM) as of last quarter is 12
AYTU BIOPHARMA INC ( AYTU ) Annual Working Capital Investments ($MM) are 0
AYTU BIOPHARMA INC ( AYTU ) Book Value ($MM) as of last quarter is 29
AYTU BIOPHARMA INC ( AYTU ) Debt/Capital as of last quarter is 41%
Other Balance Sheet Stats:
AYTU BIOPHARMA INC ( AYTU ) has 20 million in cash on hand as of last quarter
AYTU BIOPHARMA INC ( AYTU ) has 61 million of liabilities due within 12 months, and long term debt 12 as of last quarter
AYTU BIOPHARMA INC ( AYTU ) has 9 common shares outstanding as of last quarter
AYTU BIOPHARMA INC ( AYTU ) has 0 million USD of preferred stock value
Academic Scores:
AYTU BIOPHARMA INC ( AYTU ) Altman Z-Score is -3.39 as of last quarter
AYTU BIOPHARMA INC ( AYTU ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
AYTU BIOPHARMA INC ( AYTU ) largest shareholder is WELLS FARGO & COMPANY/MN owning 124 shares at 0.00 ($MM) value
Greg Pyszczymuka(an insider) Bought 12000 shares of AYTU BIOPHARMA INC ( AYTU ) for the amount of $22440.00 on 2023-06-16
2.44% of AYTU BIOPHARMA INC ( AYTU ) is held by insiders, and 34.04% is held by institutions
AYTU BIOPHARMA INC ( AYTU ) went public on 2017-02-01
Other AYTU BIOPHARMA INC ( AYTU ) financial metrics:
FCF:-2.50
Unlevered Free Cash Flow:0.00
EPS:0.65
Operating Margin:-5.61
Gross Profit Margin:72.31
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:19.77
Beta:-1.79
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AYTU BIOPHARMA INC ( AYTU ) :
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor preion supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.